← Leaderboards
Sharlene M Day
University Of Michigan At Ann Arbor
$8,991,177
Attributed
$12,745,103
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,745,103 · 7
By mechanism
R01$10,251,914 · 4
R33$1,352,130 · 1
T32$770,155 · 1
R61$370,904 · 1
Top collaborators
- Michael John Ackerman5 shared
- Rachel Lampert5 shared
- Thomas P Cappola1 shared
- Rajan Jain1 shared
- Daniel Patrick Kelly1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- David Eric Sandberg$9,835,385
- Reshma Jagsi$6,831,946
- Sarah T Hawley$8,177,059
- Colter M.s. Mitchell$10,069,662
- Lauren M Gaydosh$1,192,591
Others in their field
Top investigators on “Cardiac”
- Judith S Hochman · New York University School Of Medicine$110,228,771
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$69,868,084
- Rose A Gubitosi-Klug · Case Western Reserve University$61,225,818
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,141,827
- Joseph C Wu · Stanford University$53,027,789
- Pamela Susan Douglas · Duke University$51,506,531
Research focus
CardiacHeartHeart FailureHypertrophic CardiomyopathyCardiovascular SystemGeneticProtein DegradationSarcomeresCardiac MyocytesInsightRegistriesRegulationArrhythmiaGenesProteinsCessation Of LifeResearch PersonnelReportingFunctional DisorderIn VivoOxidationDisease ProgressionBenefits And RisksMutant
Grant awards (19)
Training Program in Cardiovascular Biology and Medicine$770,155
T32 · FY2025 · HL
Risk Alleles in Protein Quality Control Genes as Modifiers of Hypertrophic Cardiomyopathy$722,735
R01 · FY2025 · HL · contact PI
Missense Variants in Myosin Binding Protein C that Cause Hypertrophic Cardiomyopathy$703,074
R01 · FY2025 · HL · contact PI
SGLT-inhibitors in patients with hypertrophic cardiomyopathy$685,334
R33 · FY2025 · HL · contact PI
Risk Alleles in Protein Quality Control Genes as Modifiers of Hypertrophic Cardiomyopathy$749,824
R01 · FY2024 · HL · contact PI
Missense Variants in Myosin Binding Protein C that Cause Hypertrophic Cardiomyopathy$680,567
R01 · FY2024 · HL · contact PI
SGLT-inhibitors in patients with hypertrophic cardiomyopathy$666,796
R33 · FY2024 · HL · contact PI
Missense Variants in Myosin Binding Protein C that Cause Hypertrophic Cardiomyopathy$716,788
R01 · FY2023 · HL · contact PI
SGLT-inhibitors in patients with hypertrophic cardiomyopathy$370,904
R61 · FY2023 · HL · contact PI
Exercise in Genetic Cardiovascular Conditions$692,004
R01 · FY2019 · HL
Exercise in Genetic Cardiovascular Conditions$749,347
R01 · FY2018 · HL
Exercise in Genetic Cardiovascular Conditions$749,253
R01 · FY2017 · HL
Exercise in Genetic Cardiovascular Conditions$1,227,724
R01 · FY2016 · HL
Exercise in Genetic Cardiovascular Conditions$1,346,137
R01 · FY2015 · HL
Regulation of Proteasome Function in Cardiomyopathies$362,997
R01 · FY2013 · HL · contact PI
Regulation of Proteasome Function in Cardiomyopathies$381,410
R01 · FY2012 · HL · contact PI
Regulation of Proteasome Function in Cardiomyopathies$385,372
R01 · FY2011 · HL · contact PI
Regulation of Proteasome Function in Cardiomyopathies$385,477
R01 · FY2010 · HL · contact PI
Regulation of Proteasome Function in Cardiomyopathies$399,205
R01 · FY2009 · HL · contact PI